Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen in US Black/African American & Hispanic Patients With Elevated Lp(a) and ASCVD
NCT06267560Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein(a) (Lp(a)) comparing TQJ230 with Placebo (2 arms). Primary endpoint: Change in log-transformed Lp(a) concentration at 52 weeks. Started Apr 2024; status: completed.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT06267560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267560.